Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock

Core Viewpoint - Vor Biopharma Inc. has announced a public offering of 10,000,000 shares at a price of $10.00 per share, aiming to raise gross proceeds of $100 million before expenses [1] Group 1: Offering Details - The offering is expected to close on or about November 12, 2025, subject to customary closing conditions [1] - Vor Biopharma has granted underwriters a 30-day option to purchase an additional 1,500,000 shares at the public offering price [1] - The shares are being offered under a shelf registration statement declared effective by the SEC on March 31, 2025 [3] Group 2: Company Overview - Vor Biopharma is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases [5] - The company is advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development [5]